Oric Pharmaceuticals
Sandy Koppenol has a wide range of work experience in the field of pharmaceuticals. They have held positions in various companies, including ORIC Pharmaceuticals Inc., Gilead Sciences, Oncothyreon, Inc., Ikaria, Inc., Nastech Pharmaceutical, and ICOS Corporation. In these roles, Sandy has served as a Principal Scientist, Director of Formulation and Drug Delivery, City Council member, and Associate Director. Their expertise lies in formulation chemistry and drug delivery.
Sandy Koppenol obtained a Bachelor of Science degree and a Pharmacy degree, R.Ph, from the University of the Sciences in Philadelphia, during the period between 1985 to 1990. Following this, Sandy pursued further education at the University of Wisconsin-Madison from 1990 to 1996, where they successfully completed a PhD in Pharmacy.
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.